Thromboxane synthase activity and platelet function after furegrelate administration in man

Area of Science:

• Pharmacology
• Biochemistry

Background:

• Thromboxane synthase plays a key role in platelet aggregation and thrombosis.
• Inhibitors of thromboxane synthase are potential therapeutic agents for cardiovascular diseases.

Purpose of the Study:

• To evaluate the efficacy and pharmacokinetic profile of furegrelate sodium, a novel thromboxane synthase inhibitor, in healthy male subjects.
• To assess the dose-related effects of furegrelate sodium on thromboxane synthesis and platelet aggregation.

Main Methods:

• Oral administration of furegrelate sodium in single doses ranging from 200 to 1600 mg to normal male subjects.
• Ex vivo measurement of thromboxane synthesis from platelet-rich plasma (PRP) and in vivo measurement from urine.
• Assessment of platelet aggregation, bleeding times, and coagulation parameters.

Main Results:

• Furegrelate sodium demonstrated dose-related inhibition of thromboxane synthesis for 8-12 hours.
• Significant inhibition of platelet aggregation was observed, though with variability.
• The drug was well absorbed orally, with a Tmax of 1 hour and a half-life (t1/2) of 3.5 to 5 hours.
• Elimination was primarily via renal excretion of the parent compound, with no marked metabolism.

Conclusions:

• Furegrelate sodium is an effective thromboxane synthase inhibitor in humans.
• The compound possesses favorable pharmacokinetic properties, including good oral absorption and a relatively long biologic and circulating half-life.
• Further investigation into its therapeutic potential for conditions involving excessive thromboxane production is warranted.